Head-To-Head Contrast: Medicure (OTCMKTS:MCUJF) versus Sigyn Therapeutics (OTCMKTS:SIGY)

Insider and Institutional Ownership

10.0% of Sigyn Therapeutics shares are owned by institutional investors. 12.9% of Medicure shares are owned by company insiders. Comparatively, 78.5% of Sigyn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Medicure and Sigyn Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicure	-21.65%	-44.34%	-26.22%
Sigyn Therapeutics	N/A	N/A	-3,743.20%

Earnings & Valuation

This table compares Medicure and Sigyn Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicure	$20.65 million	0.41	-$5.08 million	($0.47)	-1.71
Sigyn Therapeutics	N/A	N/A	-$3.34 million	($4.19)	-0.01

Sigyn Therapeutics has lower revenue, but higher earnings than Medicure. Medicure is trading at a lower price-to-earnings ratio than Sigyn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Sigyn Therapeutics beats Medicure on 6 of the 9 factors compared between the two stocks.

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.